RTI Surgical posted 1Q19 orthopedic revenue of USD $60MM, +0.2% vs 1Q18.
- Completed the acquisition of Paradigm Spine
- Focusing on accelerated reimbursement, physician engagement and salesforce execution to drive sales of coflex Interlaminar Stabilization device acquired from Paradigm
- Restructured and expanded commercial team
- 2019 guidance for all revenue in the range of $325MM to $335MM, +15% to +19% growth compared to 2018
Estimated segment sales and growth on an as-reported basis are as follows ($MM).
1Q19 | 1Q18 | $ Chg | % Chg | |
Spine | $24.1 | $23.4 | $0.7 | 3.0% |
Orthobiologics | $35.9 | $36.5 | -$0.6 | -1.7% |
Total | $60.0 | $59.9 | $0.1 | 0.2% |
Revenue by geographic region is as follows ($MM).
Geographic Region | 1Q19 | 1Q18 | $ Chg | % Chg |
US | $54.0 | $53.8 | $0.2 | 0.3% |
Ex-US | $6.0 | $6.1 | -$0.1 | -1.1% |
Total | $60.0 | $59.9 | $0.1 | 0.2% |
Net earnings, inclusive of all revenue, are as follows.
1Q19 | Amount ($MM) | % of Sales |
Sales | $69.7 | |
Cost of Sales | -$31.7 | 45.5% |
Selling and Admin | -$31.9 | 45.7% |
R & D | -$4.3 | 6.2% |
Other | -$10.9 | 15.6% |
Net Earnings | -$9.1 | -13.0% |
Source: RTI Surgical; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
RTI Surgical posted 1Q19 orthopedic revenue of USD $60MM, +0.2% vs 1Q18.
Completed the acquisition of Paradigm Spine
Focusing on accelerated reimbursement, physician engagement and salesforce execution to drive sales of coflex Interlaminar Stabilization device acquired from Paradigm
Restructured and expanded commercial team
2019...
RTI Surgical posted 1Q19 orthopedic revenue of USD $60MM, +0.2% vs 1Q18.
- Completed the acquisition of Paradigm Spine
- Focusing on accelerated reimbursement, physician engagement and salesforce execution to drive sales of coflex Interlaminar Stabilization device acquired from Paradigm
- Restructured and expanded commercial team
- 2019 guidance for all revenue in the range of $325MM to $335MM, +15% to +19% growth compared to 2018
Estimated segment sales and growth on an as-reported basis are as follows ($MM).
1Q19 | 1Q18 | $ Chg | % Chg | |
Spine | $24.1 | $23.4 | $0.7 | 3.0% |
Orthobiologics | $35.9 | $36.5 | -$0.6 | -1.7% |
Total | $60.0 | $59.9 | $0.1 | 0.2% |
Revenue by geographic region is as follows ($MM).
Geographic Region | 1Q19 | 1Q18 | $ Chg | % Chg |
US | $54.0 | $53.8 | $0.2 | 0.3% |
Ex-US | $6.0 | $6.1 | -$0.1 | -1.1% |
Total | $60.0 | $59.9 | $0.1 | 0.2% |
Net earnings, inclusive of all revenue, are as follows.
1Q19 | Amount ($MM) | % of Sales |
Sales | $69.7 | |
Cost of Sales | -$31.7 | 45.5% |
Selling and Admin | -$31.9 | 45.7% |
R & D | -$4.3 | 6.2% |
Other | -$10.9 | 15.6% |
Net Earnings | -$9.1 | -13.0% |
Source: RTI Surgical; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.